Obstructive Sleep Apnea (OSA) Emerging Research and Trials to Watch

What Counts as Emerging in OSA

Obstructive sleep apnea occurs when the upper airway repeatedly collapses during sleep, causing airflow reduction, oxygen desaturation, arousals, sleep fragmentation, and daytime consequences. Emerging research is not a license to skip diagnosis. The practical pathway still starts with symptoms, risk factors, clinical assessment, and objective testing through polysomnography or a validated home sleep apnea test when appropriate.

The most important current distinction is between approved care and investigational care. An FDA approval, an AASM guideline, and a mechanistic physiology paper answer different questions. Treatment decisions depend on keeping those categories separate.

Positive Airway Pressure Remains the Standard Anchor

The American Academy of Sleep Medicine clinical practice guideline for adults recommends positive airway pressure for adults with OSA and excessive sleepiness, and it supports PAP use in adults with impaired sleep-related quality of life or comorbid hypertension. [1] PAP is not glamorous, but it has the deepest evidence base and is adjustable across disease severity.

Adherence remains the central challenge. Modern devices can track use, mask leak, residual events, and pressure needs, which helps clinicians troubleshoot rather than declaring PAP failure after one poor mask experience. Common fixes include mask refitting, humidification, pressure adjustment, nasal obstruction treatment, and behavioral support.

Tirzepatide Changed the Medication Field

In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication for moderate-to-severe OSA in adults with obesity. The approval was based on two randomized, double-blind, placebo-controlled trials that studied adults for 52 weeks, including one trial in participants using PAP and one in participants unable or unwilling to use PAP. [2] The peer-reviewed SURMOUNT-OSA report found reductions in apnea-hypopnea index and other prespecified outcomes, with gastrointestinal adverse events occurring frequently. [5]

This is a major development, but it has limits. The indication is tied to adults with obesity and moderate-to-severe OSA. Tirzepatide should be used with reduced-calorie diet and increased physical activity, and it does not automatically replace PAP for every patient. A systematic review predating tirzepatide found that lifestyle interventions can improve OSA severity, reinforcing that weight-related care is broader than one drug. [8] None of this proves that compounded incretin products, unrelated supplements, or off-label peptide protocols treat OSA.

Phenotypes and Endotypes: Useful, Not Yet a Home Protocol

Eckert and colleagues' 2013 physiology study helped define distinct causes of OSA and showed that OSA is not purely an anatomy problem. Traits such as upper-airway collapsibility, loop gain, arousal threshold, and muscle responsiveness can differ across patients. [3]

That research is valuable because it points toward targeted therapy. For example, a patient whose OSA is driven mainly by anatomy may respond differently from a patient whose condition is strongly influenced by ventilatory control instability. But phenotype papers do not establish that a reader should use a sedative, carbonic anhydrase inhibitor, oxygen, supplement, or device without a sleep specialist. They are discovery and targeting evidence, not retail instructions.

Devices and Procedures Under Active Refinement

The AASM and American Academy of Dental Sleep Medicine guideline supports oral appliances for adults with OSA who are intolerant of CPAP or prefer an alternative, with qualified dental oversight and follow-up testing. [6] Hypoglossal nerve stimulation improved objective and patient-reported outcomes in the carefully selected adults enrolled in the STAR trial, but candidacy depends on anatomy, apnea severity, central apnea burden, and other criteria. [7] Trial expansion and real-world registry work continue to refine who benefits most.

Alternative therapies are not automatically easier versions of CPAP; they have selection criteria. The right device for one patient can fail another if the underlying anatomy or physiology is different.

Diagnostics Are Also Changing

Home sleep apnea testing has broadened access, and wearable signals are improving. Still, consumer sleep trackers do not diagnose OSA by themselves. They may reveal snoring, oxygen trends, heart-rate changes, or sleep fragmentation that justifies medical evaluation. A validated home test or in-lab polysomnogram is still needed when results will guide treatment; our OSA diagnosis guide explains how those pathways differ. The AASM diagnostic guideline recommends polysomnography or technically adequate home sleep apnea testing for uncomplicated adults at increased risk and identifies situations in which polysomnography is preferred. [4]

Research on oximetry, airflow, acoustics, and machine-learning interpretation may reduce bottlenecks in the future. The risk is overconfidence: a low-quality signal can miss disease, underestimate severity, or fail to distinguish obstructive from central events. Diagnostic innovation is most useful when it feeds into a clinician-reviewed care pathway.

Registered Trials to Watch

Registry status changes, so this inventory is dated August 4, 2026:

• MARITIME-OSA-2, NCT07226765: Recruiting. This phase 3 placebo-controlled trial is evaluating maridebart cafraglutide in an estimated 250 adults with OSA and overweight or obesity who are not using PAP. [9]
• MARITIME-OSA-1, NCT07225686: Recruiting. Its companion phase 3 trial is enrolling an estimated 250 adults who remain on PAP, which should help separate an add-on strategy from a non-PAP population. [10]
• AD109 continuation, NCT06566820: Enrolling by invitation. This open-label phase 3 continuation follows eligible participants from parent AD109 trials and emphasizes longer-term adverse events; it is not a general-access efficacy trial. [11]
• CHOSA, NCT07600333: Not yet recruiting. This pediatric trial plans to compare CPAP with high-flow nasal cannula in 258 children with moderate-to-severe OSA under home-use conditions. [12]
• SURMOUNT-ADOLESCENTS-2, NCT06439277: Recruiting. This is an obesity and comorbidity trial in adolescents, not a dedicated pediatric OSA approval trial; change in peripheral AHI is a secondary outcome. [13]

Medication research also extends beyond incretins. The completed phase 2 FLOW trial found a dose-related AHI reduction with sultiame, but phase 2 results do not establish FDA approval, long-term benefit, or a role outside research. [14] Pediatric evidence must remain distinct from adult evidence: the PATS randomized trial of adenotonsillectomy versus watchful waiting in children with mild sleep-disordered breathing found no significant improvement in its two primary neurocognitive outcomes, while several secondary outcomes improved. [15] The registered pediatric studies above address different questions and cannot be collapsed into an adult treatment recommendation.

What Patients Should Watch

The most meaningful trial outcomes are not just AHI reduction. Look for oxygen burden, sleepiness, quality of life, blood pressure, cardiovascular outcomes, adverse events, adherence, and whether results apply to the population in question. A trial in adults with obesity may not apply to a lean patient with craniofacial narrowing. A procedure trial in carefully selected adults may not apply to adolescents, central sleep apnea, or severe cardiopulmonary disease.

Bottom Line

OSA care is becoming more personalized, and tirzepatide has created the first approved medication pathway for a defined adult population. The evidence hierarchy still matters: PAP is guideline-backed, Zepbound has an FDA-labeled OSA indication for adults with obesity, devices require selection criteria, and phenotype research is a map for future targeting rather than an established treatment protocol.